Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O’Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian
{"title":"PROACT 2.0:改善临床试验中医患沟通的新型开源工具","authors":"Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O’Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian","doi":"10.1177/03008916241248007","DOIUrl":null,"url":null,"abstract":"The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials\",\"authors\":\"Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O’Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian\",\"doi\":\"10.1177/03008916241248007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.\",\"PeriodicalId\":23450,\"journal\":{\"name\":\"Tumori Journal\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tumori Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/03008916241248007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03008916241248007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials
The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.